Program will be added once finalised.
DAY 2
Friday, 23 October 2026
8h30
Welcome coffee
9h00
Opening Keynotes
- Plenary
Chairman
9h00
Platform, Analytics and Network Readiness for the 100 Days Mission
Ingrid Kromann
Senior Advisor in Process Development and Manufacturing (PDM) Division
CEPI - Denmark
9h30
Diagnostics Manufacturing in Africa for Health Security Strengthening
Cheikh Tidiane Diagne
Head of DIATROPIX
Pasteur Institute of Dakar - Senegal
10h00
Breakthrought Innovation session 1
- Plenary
Chaired by Christophe Jacquinet and Philippe Leissner - IDCluster
10h00
Opening Remarks
Christophe Jacquinet
General Manager
Infectious Diseases Cluster - France
Philippe Leissner
Head of Development & Partnerships
Infectious Diseases Cluster - France
10h10
Rapid and comprehensive in-vitro diagnosis of bacteraemia or fungemia responsible for Sepsis
Hervé Brochette
CEO
WEZION - France
10h20
NextGenFluVax – Combine OVX836 T-cell response against the Nucleoprotein with seasonal flu Vaccine to enhance protective efficacy
Florence Nicolas
Chief Scientific Officer
Osivax - France
10h30
Mosaic nanoparticle immunization drives broad pan-sarbecovirus activity of equine polyclonal F(ab’)₂ antibodies
Noémie Aurine
R&D Project leader
Fab'entech - France
10h00
Titre de la présentation
Prénom NOM
Fonction
Entreprise, Pays
10h40
Coffe Break - Exhibition Hall
11h15
Track 5: Alternative to current antibiotics
- Plenary
Chaired by Francesca Bernardini - CARB-X and Derry Mercer - INCATE
11h15
ANP (Atrial Natriuretic Peptide), a powerful, safe and affordable solution against Pseudomonas
aeruginosa biofilms: mechanism of action and therapeutic potential.
Olivier Lesouhaitier
CSO
Hermione Therapeutics - France
11h35
Fighting Infection Without Antibiotics or Antivirals:
Bioinspired Supramolecular Interfaces for the Post-Antimicrobial Era
Nihal Engin Vrana
CEO
Spartha Medical - France
11h55
Understanding Immune Responses to Improve Vaccine Development
Adam Cunningham
Professor of Functional Immunity and Co-Director of the BactiVac Network
University of Birmingham - United Kingdom
12h15
Q&A session
12h30
Lunchbreak - Exhibition Hall
14h00
Breakthrought Innovation session 2
- Plenary
Chaired by Christophe Jacquinet and Perrine Jeantet - IDCluster
14h00
Towards Clinical Development of a Broad-Spectrum Antibody Against the Four Orthopoxvirus Species Infectious to Humans: The THANATOS Project
Kelly Meneyrol
Engineer - PhD Student
IRBA - France
14h10
Breath based diagnostics of winter respiratory viruses
Joao Trabuco
Chief Technology Officer
nawu diagnostics - France
14h20
FlashRNA, a novel RNA delivery platform for prophylactic and therapeutic immunization: preliminary in vivo evaluation in infectious disease and oncology models
Christine Duthoit
Co founder – CEO – CSO
RNALead - France
14h30
DNA-based Vaccines in the Era of Epidemic Preparedness
Antonella Conforti
Principal Investigator
Takis - Italy
14h40
Track 6: Immunotherapies & new biotherapeutics
- Plenary
Chaired by Francesca Bernardini - CARB-X and Derry Mercer - INCATE
14h40
Beyond Surface Antigens :Targeting Immunosuppressive Proteins for Next Generation Immunotherapies
Ana Fidalgo
Research Scientist
Immunethep - Portugal
15h00
Anti-virulence and bacterial clearance
Alaa Alhayek
Postdoctoral researcher
Biozentrum Basel - Switzerland
15h20
Unlocking the potential of mRNA for antibody synthesis within the body
Bruno Pitard
Researcher
Nantes University - France
15h40
Q&A session
16h00